Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Forma And Cubist Target Antibacterials

by Michael McCoy
February 2, 2009 | A version of this story appeared in Volume 87, Issue 5

Forma Therapeutics and Cubist Pharmaceuticals will work together to discover novel antibacterial compounds for development by Cubist. Forma was created just last month by scientists from the Broad Institute of Harvard and MIT to combine biology and chemistry for drug discovery. Under the deal with Cubist, Forma will receive up to $14 million in payments and research funding over three years. It could get an additional $54 million in milestone and royalty payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.